Lainate – 5 April 2018 – Cassiopea SpA (SIX: SKIN), a clinical stage specialty pharmaceutical company focused on developing innovative and differentiated medical dermatology products, announces the results of the 2018 annual ordinary shareholders meeting as well as of the extraordinary shareholder meeting held today in Lainate, Milan (Italy). About 53,2% of Cassiopea’s total capital of 10,000,000 shares were represented at the meetings.
In the ordinary shareholders meeting the shareholders of the Company approved the financial statements for the year 2017 as per 31 December 2017, elected the following candidates as members of the Board of Directors: Jan de Vries (incumbent, non-executive, independent), Pierpaolo Guzzo (incumbent, non-executive, independent), Oyvind Bjordal (incumbent, non-executive, independent), Diana Harbort (incumbent, executive), and Maurizio Baldassarini (new, non-executive, independent) and appointed BDO Italia S.p.A. as the external auditors. No other items were on the agenda.
In the extraordinary shareholders meeting, the shareholders approved the increase of the share capital by 10%, from EUR 10,000,000 to EUR 11,000,000.
About Cassiopea
Cassiopea SpA is a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products. Our focus is on the topical treatment of acne, androgenic alopecia (or AGA) and genital warts. The portfolio comprises four unencumbered clinical candidates, for which Cassiopea owns the worldwide rights. The company plans to commercialize the products directly in the US and partner the products outside of the US. For further information on Cassiopea, please visit www.cassiopea.com.
Next events
2018 Half Year Report 24 July 2018
Contact:
Dr. Chris Tanner, CFO and Head of Investor Relations
Tel: +39 02 868 91 124
Some of the information contained in this press release may contain forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cassiopea has no obligation to publicly update or revise any forward-looking statements.
